Publicaciones en las que colabora con Javier Cortés Castán (48)

2023

  1. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

    Annals of Oncology

2022

  1. Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

    BMC Cancer, Vol. 22, Núm. 1

2021

  1. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

    npj Breast Cancer, Vol. 7, Núm. 1

  2. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428

  2. Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals

    Frontiers in Oncology, Vol. 10

  3. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    The Lancet Oncology, Vol. 21, Núm. 4, pp. 519-530

2019

  1. Corrigendum: Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis (Annals of Oncology (2012) 23 (1130-1137) DOI: 10.1093/annonc/mdr432)

    Annals of Oncology

2018

  1. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    EMBO Molecular Medicine, Vol. 10, Núm. 12

  2. P95HER2–T cell bispecific antibody for breast cancer treatment

    Science Translational Medicine, Vol. 10, Núm. 461

  3. Perspectives on preoperative systemic treatment and breast conservative surgery: One step forward or two steps back?

    Breast, Vol. 41, pp. 133-135

  4. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1203-1210

2017

  1. 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial

    Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441

  2. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

  3. Critically short telomeres and toxicity of chemotherapy in early breast cancer

    Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482

  4. Role of total tumour load of sentinel lymph node on survival in early breast cancer patients

    Breast, Vol. 33, pp. 8-13

2016

  1. Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response

    Annals of Surgical Oncology, Vol. 23, Núm. 12, pp. 3831-3837

  2. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

    Annals of Oncology, Vol. 27, Núm. 11, pp. 2046-2052

  3. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

    Oncotarget, Vol. 7, Núm. 35, pp. 56295-56308

  4. Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts

    Oncotarget, Vol. 7, Núm. 42, pp. 67956-67965